title: [Assessment of gastrointestinal toxicity at patients with breast cancer receiving Taksans chemotherapy and doxorubicin].
abstract: The aim--assessment of gastrointestinal toxicity frequency of damaged mucosa of the colon. Type of study. A retrospective multicenter case-control study on the model of neoadjuvant and adjuvant chemotherapy for breast cancer.
  
  
  METHODS
  Over the period 1993-2003 gg. were surveyed 1643 women (average age 52.3 +/- 2.8 years).
  
  
  RESULTS
  It was revealed that the frequency of acute inflammatory and destructive changes in the mucous membrane of the colon in the course of chemotherapy was 13.6%. Frequency of sharp changes in the mucosa of the colon recording was increased almost in 10 times the rate of neoadjuvant to adjuvant that may be related to the cumulative effect of cytostatics. Revealed a higher incidence of toxicity in patients with a history of functional pathology of the intestine, which reached 22.7%. In these patients, the trigger mechanism of toxicity was the beginning of chemotherapy, and no increase in cumulative dose. All patients with inflammatory bowel disease had reported clinical signs of relapse during treatment. Noted a direct correlation between the severity of diarrhea and the severity of rectal (colitis).
  
  
  CONCLUSIONS
  Damage to mucous membrane of the colon occurs often, growing over time (from course to course), to a greater extent in patients with diarrheal syndrome.
authors.forename: I A
authors.initials: IA
authors.lastname: Koroleva
authors.forename: L Z
authors.initials: LZ
authors.lastname: Vel'sher
authors.forename: A N
authors.initials: AN
authors.lastname: Kaziulin
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Kucheriavyĭ
authors.forename: T S
authors.initials: TS
authors.lastname: Oganesian
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D003108:Colonic Diseases / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology / Q000503:physiopathology; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D004317:Doxorubicin